Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6647-6653

  Schieferdecker, Aneta ^a   Voigt, Mareike ^a   Riecken, Kristoffer ^a   Braig, Friederike ^a   Schinke, Thorsten ^a   Loges, Sonja ^a   Bokemeyer, Carsten ^a   Fehse, Boris ^a   Binder, Mascha ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Denosumab; Epitope; Monoclonal antibody; OPG; RANK; RANKL

Indexed keywords

DENOSUMAB; EPITOPE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; MONOCLONAL ANTIBODY; PEPTIDE; PEPTIDE LIBRARY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; MOLECULAR MODEL; MOLECULAR RECOGNITION; MUTATIONAL ANALYSIS; PHAGE DISPLAY; PROTEIN LOCALIZATION; PROTEIN MOTIF; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; ANTAGONISTS AND INHIBITORS; BINDING SITE; BONE NEOPLASMS; CHEMICAL STRUCTURE; EPITOPE MAPPING; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; PEPTIDE LIBRARY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES; BONE NEOPLASMS; EPITOPE MAPPING; EPITOPES; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; OSTEOPROTEGERIN; PEPTIDE LIBRARY; PEPTIDES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SEQUENCE ANALYSIS, PROTEIN;

EID: 84907069363     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2160     Document Type: Article

References (22)

1. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J and Dansey R. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012; 11(5):401-419.
2. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ and Suda T. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone. 1999; 25(5):517-523.
3. Luan X, Lu Q, Jiang Y, Zhang S, Wang Q, Yuan H, Zhao W, Wang J and Wang X. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol. 2012; 189(1):245-252.
4. Nelson CA, Warren JT, Wang MW, Teitelbaum SL and Fremont DH. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure. 2012; 20(11):1971-1982.
5. Ta HM, Nguyen GT, Jin HM, Choi J, Park H, Kim N, Hwang HY and Kim KK. Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc Natl Acad Sci U S A. 2010; 107(47):20281-20286.
6. Ito S, Wakabayashi K, Ubukata O, Hayashi S, Okada F and Hata T. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J Biol Chem. 2002; 277(8):6631-6636.
7. Lam J, Nelson CA, Ross FP, Teitelbaum SL and Fremont DH. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest. 2001; 108(7):971-979.
8. Leibbrandt A and Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008; 1143:123-150.
9. Rachner TD, Khosla S and Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011; 377(9773):1276-1287.
10. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012; 379(9810):39-46.
11. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S and Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28(35):5132-5139.
12. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29(9):1125-1132.
13. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M and Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008; 26(30):4875-4882.
14. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ and Goessl C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361(8):745-755.
15. Huang J, Gutteridge A, Honda W and Kanehisa M. MIMOX: a web tool for phage display based epitope mapping. BMC Bioinformatics. 2006; 7:451.
16. Tanaka S, Nakamura K, Takahasi N and Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 2005; 208:30-49.
17. Moreau V, Granier C, Villard S, Laune D and Molina F. Discontinuous epitope prediction based on mimotope analysis. Bioinformatics. 2006; 22(9):1088-1095.
18. Binder M, Otto F, Mertelsmann R, Veelken H and Trepel M. The epitope recognized by rituximab. Blood. 2006; 108(6):1975-1978.
19. Trepel M, Martens V, Doll C, Rahlff J, Gosch B, Loges S and Binder M. Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma. PLoS One. 2012; 7(2):e31998.
20. Weber K, Bartsch U, Stocking C and Fehse B. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther. 2008; 16(4):698-706.
21. Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C and Binder M. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia. 2012; 14(11):1023-1031.
22. Beyer WR, Westphal M, Ostertag W and von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol. 2002; 76(3):1488-1495.